← Back to Search

JAK2/STAT3 Inhibitor

WP1066 for Brain Tumor

Phase 1
Waitlist Available
Led By Tobey MacDonald, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 months post-intervention
Awards & highlights

Summary

This trial is testing WP1066, a new drug, to help children with brain tumors that don't respond to other treatments. WP1066 works by blocking a pathway that helps cancer cells grow and hide from the immune system.

Eligible Conditions
  • Brain Tumor
  • Medulloblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 months post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 months post-intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in safety and tolerability of WP1066: Maximum tolerated dose (MTD) and Dose limiting toxicities (DLT)
Maximum tolerated dose (MTD) of WP1066
Secondary study objectives
Change in Immunological response
Change in overall response rate (ORR) of WP1066 treatment
Change in overall survival (OS)
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: WP1066Experimental Treatment1 Intervention
There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8 and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
WP1066
2020
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,679 Previous Clinical Trials
2,583,656 Total Patients Enrolled
CURE Childhood Cancer, Inc.OTHER
4 Previous Clinical Trials
219 Total Patients Enrolled
Peach Bowl LegACy FundUNKNOWN
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top